Earnings Call InsightsCryoport outlines $190M–$194M 2026 revenue target as commercial cell therapy drives growthMar. 03, 2026 11:42 PM ETCryoport, Inc. (CYRX) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Cryoport, Inc. (CYRX) Q4 2025 Management View CEO Jerrell Shelton reported "full year revenue from continuing operations of $176.2 million, exceeding the high end of our prior guidance and reflecting continued momentum across our core markets." Shelton highlighted double-digit re ...

Core Viewpoint - Belgian drugmaker UCB has entered into a licensing agreement with Antengene for the experimental autoimmune disease therapy ATG-201, involving an upfront payment of $60 million and potential additional payments exceeding $1.1 billion based on milestone achievements [1]. Company Summary - UCB has secured a worldwide license for ATG-201, which targets B-cell-related autoimmune diseases, and will oversee its development, manufacturing, and commercialization [1]. - Antengene plans to submit clinical trial applications for ATG-201 in Australia and China in the first quarter of 2026, with further development to be transferred to UCB after completing phase I trials [1]. Financial Terms - The agreement includes an upfront fee of $60 million, with additional payments contingent on specific conditions and milestones, as well as royalties based on net sales [1]. - The total potential value of the deal could exceed $1.1 billion if certain milestones are met [1].

Financial Data and Key Metrics Changes - The company reported full year revenue from continuing operations of $176.2 million, exceeding the high end of prior guidance, reflecting strong momentum across core markets [13] - The gross margin improved to 47%, with a $12 million year-over-year improvement in adjusted EBITDA [19] Business Line Data and Key Metrics Changes - Revenue from commercial cell and gene therapy increased by 29% year-over-year to a record $33.4 million, representing 20% of overall revenue in Q4 [14][15] - Clinical trial revenue grew 14% year-over-year to $47.1 million, supporting a record 760 clinical trials and 20 commercial therapies worldwide [15][121] - Revenue from life sciences services segment increased by 18% year-over-year, including a 22% growth in biostorage and bioservices revenue [18][121] - The life sciences product segment saw a 7% year-over-year revenue growth [20] Market Data and Key Metrics Changes - The company supports approximately 70% of total clinical trials in the cell and gene therapy industry, with a significant pipeline of 86 clinical trials in phase 3 and 361 in phase 2 [16][121] - The company anticipates 13 BLA or MAA application filings in 2026, with 2 already filed [16] Company Strategy and Development Direction - The company aims to expand services in life sciences by broadening revenue streams and capturing more revenue per client [18] - Strategic partnerships with DHL, Cardinal Health, and Parexel are expected to enhance market position and drive standardization in the cell and gene therapy ecosystem [27][29][88] - The company is leveraging generative AI to enhance internal workflows and operations [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2026, with full year revenue guidance set at $190 million to $194 million [30] - The company expects to achieve positive adjusted EBITDA in the second half of 2026 [30] - Management noted that the macro environment remains volatile but sees strong interest in services provided [68] Other Important Information - The financials of CRYOPDP are now presented as discontinued operations following its sale to DHL [9] - The company is investing in global supply chain centers in Paris and California to enhance service capabilities [24] Q&A Session Summary Question: Guidance on growth in biologics and services - Management expects continued progress with existing customers and new commercial therapies, with commercial revenue growing by 29% in 2025 [38][39] Question: Clarification on Q1 expectations - Management reported a solid start to Q1 with no expected disruptions from geopolitical issues [50] Question: Impact of funding environment on customer orders - Funding typically influences customer orders after about a six-month lag [55] Question: Expectations for FDA approvals and growth contributions - Management indicated moderate growth from animal health and reproductive health, with cell and gene therapy being the primary growth driver [72] Question: Update on DHL partnership integration - The integration with DHL is ongoing, and full benefits will take time to materialize [83] Question: Insights on product revenue growth - Management noted that MVE's growth should be assessed on an annual basis rather than quarterly due to the nature of capital equipment purchases [101]

Financial Data and Key Metrics Changes - Cryoport reported full year revenue from continuing operations of $176.2 million, exceeding prior guidance and reflecting strong momentum across core markets [6][10] - The company achieved a gross margin of 47% and a $12 million year-over-year improvement in adjusted EBITDA [10][14] - Revenue from life sciences services segment increased 18% year-over-year, with biostorage and bioservices revenue growing by 22% [10][91] Business Line Data and Key Metrics Changes - Revenue from commercial cell and gene therapy increased by 29% year-over-year to a record $33.4 million, representing 20% of overall revenue [6][7] - Clinical trial revenue grew 14% year-over-year to $47.1 million, supporting a record 760 clinical trials and 20 commercial therapies worldwide [7][91] - Revenue from the life sciences product segment grew 7% year-over-year [10] Market Data and Key Metrics Changes - The company supports approximately 70% of total clinical trials in the cell and gene therapy industry, with a significant pipeline of 86 clinical trials in phase 3 and 361 in phase 2 [7][9] - Anticipated new therapy approvals include 9 new therapies and 11 BLA/MAA application filings in 2026 [7][14] Company Strategy and Development Direction - Cryoport aims to expand services in the life sciences sector by broadening revenue streams and enhancing operational discipline to achieve profitability [10][14] - The strategic partnership with DHL is expected to enhance Cryoport's position in APAC and EMEIA regions, leveraging DHL's global scale [13][14] - The company is actively leveraging generative AI to improve internal workflows and operational efficiency [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2026, with full year revenue guidance set at $190 million to $194 million [14] - The company is confident in its ability to achieve positive adjusted EBITDA in the second half of 2026, driven by growth in commercial therapies and operational efficiencies [10][14] Other Important Information - The financials of CRYOPDP are now presented as discontinued operations following its sale to DHL [4] - The company has made significant investments in global supply chain centers to enhance service capabilities [12] Q&A Session Summary Question: Guidance for growth in biologics and services - Management expects continued progress with existing customers and the onboarding of new commercial therapies, although specific growth percentages were not disclosed [17][20] Question: Clarification on Q1 expectations - Management indicated a solid start to Q1 with no expected disruptions from geopolitical issues [30][32] Question: Impact of funding environment on customer orders - Typically, funding impacts are seen after about a six-month lag [36][37] Question: Expectations for positive adjusted EBITDA - Positive adjusted EBITDA is anticipated due to growth initiatives and operational efficiencies rather than solely cost reductions [38][40] Question: Macro environment impact on revenue guidance - Management feels comfortable with the guidance provided, despite macroeconomic volatility [47][48] Question: Update on partnerships with DHL, Cardinal Health, and Parexel - The integration with DHL is ongoing, and partnerships with Cardinal Health and Parexel are aimed at building a supportive ecosystem for cell and gene therapy [56][63] Question: Anticipated impact of FDA changes on approvals - Streamlining the approval process is expected to benefit the company by increasing patient access to therapies [67][71] Question: MVE product revenue growth - MVE's growth is viewed on an annual basis rather than quarterly, with expectations for moderate growth in 2026 [75][78]

Revenue Growth - FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance, representing a 12% year-over-year growth[5]. - Life Sciences Services revenue grew 18% year-over-year to $96.5 million, with BioStorage/BioServices revenue rising 22% to $18.4 million[5][20]. - Revenue from commercial cell and gene therapy support increased 29% year-over-year to $33.4 million, with the company supporting a record 760 global clinical trials[3][12]. - Full-year 2026 revenue guidance is set at $190 million to $194 million, indicating an expected growth of 8% to 10% year-over-year[5][9]. - Total revenue for the three months ended December 31, 2025, was $45.450 million, compared to $41.452 million for the same period in 2024, representing a year-over-year increase of 7.2%[38]. - Life Sciences Services revenue for the year ended December 31, 2025, was $96.497 million, up from $82.044 million in 2024, reflecting a growth of 17.7%[38]. - Life Sciences Products revenue for the year ended December 31, 2025, reached $79.680 million, compared to $74.725 million in 2024, indicating a growth of 6.5%[38]. Profitability and Loss - Net income for FY 2025 was $78.3 million, primarily driven by the divestiture of the CRYOPDP business, compared to a net loss of $114.8 million in FY 2024[27]. - The Company reported a net loss of $11.644 million for the three months ended December 31, 2025, compared to a net loss of $18.669 million for the same period in 2024[38]. - The loss from operations for the year ended December 31, 2025, was $36.806 million, a significant improvement from a loss of $121.671 million in 2024[38]. - For the year ended December 31, 2025, GAAP net income was $78.301 million, compared to a loss of $114.756 million in 2024[45]. - Adjusted net loss for the three months ended December 31, 2025, was $8.521 million, an improvement from a loss of $18.670 million in the same period of 2024[45]. - Adjusted EBITDA from continuing operations for the year ended December 31, 2025, was a loss of $5.779 million, compared to a loss of $17.771 million in 2024[46]. - The company reported a GAAP loss from continuing operations of $33.969 million for the year ended December 31, 2025, compared to a loss of $104.708 million in 2024[46]. Cost Management - Operating costs for FY 2025 decreased to $119.9 million from $191.3 million in FY 2024, reflecting a significant reduction in expenses[21]. - GAAP operating costs and expenses for the year ended December 31, 2025, were $119.860 million, down from $191.328 million in 2024[44]. - Non-GAAP adjusted operating costs and expenses for the year ended December 31, 2025, were $127.519 million, compared to $119.860 million in 2024[44]. Financial Position - The company held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025[25]. - Cash and cash equivalents as of December 31, 2025, were $250.494 million, an increase from $34.000 million in 2024[39]. - The company had total current assets of $476.174 million as of December 31, 2025, compared to $571.000 million in 2024[39]. - Total liabilities as of December 31, 2025, were $262.351 million, compared to $703.492 million in 2024[39]. - Total stockholders' equity as of December 31, 2025, was $502.638 million, compared to $1.000 million in 2024[39]. Strategic Initiatives - Cryoport formed a strategic partnership with DHL Group, enhancing its positioning in the EMEA and APAC regions[8]. - The company launched a Global Supply Chain Center in Paris and expanded operations in Belgium to support key commercial clients[7]. - The Company plans to expand its global partnerships and expects revenue contributions from IntegriCell's cryopreservation service centers throughout 2026[36]. - The Company anticipates potential impacts on its business from external factors such as supply chain constraints and inflationary pressures[28]. - The Company will host a conference call on March 3, 2026, to discuss its financial results and future outlook[31].

Q4 FY-2025 Earnings Call Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospe ...

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results [Accessibility Statement] Skip Navigation- Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)- Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025- Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025- Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/Bi ...

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series [Accessibility Statement] Skip NavigationSelf-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space EnvironmentsNASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 ...

Core Insights - The article emphasizes the significant potential of cell and gene therapies (CGT) as they evolve from theoretical concepts to practical applications, highlighting the importance of the infrastructure that supports these technologies [1] Group 1: Market Themes - The investment portfolio is centered around five key themes: Semiconductor Supply Chain, Grid/Power/Energy Transition, Critical Materials, Biotechnology, and Artificial Intelligence/Cloud Computing [1] - The investment strategy combines deep value investing principles with a forward-looking approach to identify asymmetric opportunities in the market [1] Group 2: Company Focus - Cryoport, Inc. is identified as a potentially undervalued player in the CGT infrastructure sector, suggesting a promising investment opportunity [1]

Revenue Growth - Total revenue for the three months ended September 30, 2025, increased by $5.9 million, or 15.4%, to $44.2 million compared to $38.3 million in the same period of 2024[129] - Life Sciences Services revenue rose by $3.3 million, or 15.9%, from $20.9 million to $24.3 million for the three months ended September 30, 2025[131] - Commercial Cell & Gene Therapy revenue included in BioLogistics Solutions revenue was $7.4 million for the three months ended September 30, 2025, representing a 21.7% year-over-year increase from $6.1 million[131] - Life Sciences Products revenue increased by $2.6 million, or 14.9%, from $17.4 million to $20.0 million for the three months ended September 30, 2025, compared to the same period in 2024[132] - Life Sciences Services revenue increased by $10.9 million, or 18.0%, from $60.6 million to $71.5 million for the nine months ended September 30, 2025, compared to the same period in 2024[147] - Total revenue increased by $15.4 million, or 13.4%, from $115.3 million to $130.7 million for the nine months ended September 30, 2025, compared to the same period in 2024[146] - Life Sciences Products revenue increased by $4.5 million, or 8.2%, from $54.7 million to $59.2 million for the nine months ended September 30, 2025, compared to the same period in 2024[149] Financial Performance - Gross margin for the three months ended September 30, 2025, was $21.3 million, a 22.3% increase from $17.4 million in the same period of 2024[129] - Gross margin for the three months ended September 30, 2025, was 48.2% of total revenue, up from 45.5% for the same period in 2024[133] - Gross margin for Life Sciences Products revenue was 46.4% for the three months ended September 30, 2025, compared to 42.1% for the same period in 2024[135] - Net loss attributable to common stockholders was $8.9 million for the three months ended September 30, 2025, compared to a loss of $1.2 million in the same period of 2024, representing a 648.4% increase in loss[129] - Loss from continuing operations improved by $62.1 million, or 70.9%, for the nine months ended September 30, 2025, compared to the same period in 2024[146] - Adjusted EBITDA from continuing operations was a loss of $4.4 million for the nine months ended September 30, 2025, compared to a loss of $14.9 million for the same period in 2024[169] Costs and Expenses - Total cost of revenue increased by $2.0 million, or 9.7%, from $20.9 million to $22.9 million for the three months ended September 30, 2025[129] - Engineering and development expenses increased by $0.4 million, or 8.8%, for the three months ended September 30, 2025, compared to the same period in 2024[137] - SG&A expenses decreased by $6.2 million, or 7.6%, as compared to the same period in 2024[154] - Investment income decreased by $2.0 million, or 23.9%, for the nine months ended September 30, 2025, compared to the same period in 2024[146] - Investment income decreased by $2.0 million for the nine months ended September 30, 2025, compared to the prior year[156] Strategic Developments - The divestiture of the CRYOPDP business to DHL for $133.0 million was completed on June 11, 2025, enhancing the company's growth strategy in the EMEA and APAC regions[127] - The company anticipates that inflationary pressures could affect future financial performance if cost increases cannot be offset by price increases and productivity gains[128] - The company expects to continue incurring operating losses in the near term while investing in new supply chain initiatives and geographic expansion[170] Cash and Investments - As of September 30, 2025, the company had cash and cash equivalents of $255.8 million and working capital of $454.1 million[170] - Net cash provided by investing activities was $250.3 million during the nine months ended September 30, 2025, primarily due to the sale of CRYOPDP[175] - Net cash used in financing activities totaled $18.9 million during the nine months ended September 30, 2025, due to repayments and stock repurchases[176] - The company repurchased 1,111,614 shares of common stock for an aggregate purchase price of $8.0 million during the nine months ended September 30, 2025[182] - The estimated fair value of the 2026 Senior Notes was $174.5 million as of September 30, 2025[185] Foreign Exchange and International Business - International business revenue accounted for 18% of consolidated revenue, increasing by $0.4 million compared to the same period last year due to foreign exchange fluctuations[186] - As of September 30, 2025, foreign-denominated cash and cash equivalents totaled $25.2 million, with potential declines of $1.3 million, $2.5 million, and $5.0 million under 5%, 10%, and 20% adverse foreign exchange changes, respectively[187] - Short-term intercompany loan balances are exposed to foreign exchange risk, with potential losses of $0.9 million, $1.8 million, and $3.6 million under 5%, 10%, and 20% adverse foreign exchange changes, respectively[188] Clinical Trials - The company supported 745 clinical trials globally as of September 30, 2025, with 83 in Phase 3, an increase of 54 trials from 691 at the same date in 2024[131] Impairment Loss - The company recorded an impairment loss of $63.8 million related to goodwill for the MVE Biological Solutions reporting unit as of June 30, 2024[156] Discontinued Operations - Revenue from discontinued operations decreased by $21.4 million, or 39.9%, from $53.5 million to $32.2 million for the nine months ended September 30, 2025[163]